Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial.
Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial.
复制标题
艾司西酞普兰对患有潮热的健康更年期女性的更年期特异性生活质量和疼痛的影响：一项随机对照试验。
DOI：
10.1016/j.maturitas.2012.09.006
复制
发表时间：
2012
期刊：
影响因子：
4.9
通讯作者：
Ensrud,KristineE
中科院分区：
文献类型：
--
作者：
LaCroix,AndreaZ;Freeman,EllenW;Larson,Joseph;Carpenter,JanetS;Joffe,Hadine;Reed,SusanD;Newton,KatherineM;Seguin,RebeccaA;Sternfeld,Barbara;Cohen,Lee;Ensrud,KristineE
目的评价艾司西酞普兰10 ~ 20mg/d对健康绝经期潮热妇女绝经相关生活质量和疼痛的影响。研究设计：2009年7月至2010年6月，在4个临床站点招募了205名年龄在40-62岁、平均每日潮热≥4次的女性，进行了艾司西酞普兰10-20mg /天与相同安慰剂的双盲、安慰剂对照随机试验。主要结局指标先前报道的主要试验结果是8周血管舒缩症状的频率和严重程度。在这里，我们报告了预先指定的次要终点，即绝经期特定生活质量问卷（MENQOL）和疼痛强度和干扰量表（PEG）的总得分和领域得分。结果收集了97%的随机女性的结局数据，87%的女性服用了至少70%的研究药物。艾司西酞普兰治疗可显著提高MENQOL总分(8周时平均差值为- 0.41；95%可信区间(CI) - 0.71至- 0.11；p<0.001)，以及血管舒缩、社会心理和身体领域得分，其中血管舒缩领域差异最大（平均差异为- 0.75；95% CI为- 1.28至- 0.22;p=0.02）。两组在性功能方面差异无统计学意义。与安慰剂相比，艾司西酞普兰治疗导致PEG评分有统计学意义的改善（8周时治疗组平均差异为- 0.33；95% CI为- 0.81至0.15;p=0.045）。结论艾司西酞普兰10-20mg /天治疗有血管舒缩症状的健康女性，可显著改善绝经相关生活质量和疼痛。
OBJECTIVETo evaluate the effects of escitalopram 10–20mg/day on menopause-related quality of life and pain in healthy menopausal women with hot flashes.STUDY DESIGNA double-blind, placebo-controlled randomized trial of escitalopram 10–20mg/day vs. identical placebo was conducted among 205 women ages 40–62 years with an average of ≥4 daily hot flashes recruited at 4 clinical sites from July 2009 to June 2010.MAIN OUTCOME MEASURESThe primary trial outcomes, reported previously, were the frequency and severity of vasomotor symptoms at 8 weeks. Here, we report on the pre-specified secondary endpoints of total and domain scores from the Menopause-Specific Quality of Life Questionnaire (MENQOL) and the pain intensity and interference scale (PEG).RESULTSOutcome data were collected on 97% of randomized women and 87% of women took at least 70% of their study medication. Treatment with escitalopram resulted in significantly greater improvement in total MENQOL scores (mean difference at 8 weeks of −0.41; 95% confidence interval (CI) −0.71 to −0.11; p<0.001), as well as Vasomotor, Psychosocial, and Physical domain scores with the largest difference seen in the Vasomotor domain (mean difference −0.75; 95% CI −1.28 to −0.22; p=0.02). There was no significant treatment group difference for the Sexual Function domain. Escitalopram treatment resulted in statistically significant improvements in PEG scores compared to placebo (mean treatment group difference at 8 weeks of −0.33; 95% CI −0.81 to 0.15; p=0.045).CONCLUSIONSTreatment with escitalopram 10–20mg/day in healthy women with vasomotor symptoms significantly improved menopause-related quality of life and pain.
登录
查看更多内容
影响因子：
11.4
作者：
Davis, SR;Briganti, EM;Burger, HG
通讯作者：
Burger, HG
影响因子：
4.7
作者：
Carpenter, JS
通讯作者：
Carpenter, JS
DOI：
10.1097/01.gme.0000240633.46300.fa
发表时间：
2006-09
期刊：
Menopause
影响因子：
--
作者：
C. Soares;Helga Arsenio;H. Joffe;B. Bankier;P. Cassano;Laura Petrillo;L. Cohen
通讯作者：
C. Soares;Helga Arsenio;H. Joffe;B. Bankier;P. Cassano;Laura Petrillo;L. Cohen
影响因子：
11.3
作者：
BUYSSE, DJ;REYNOLDS, CF;KUPFER, DJ
通讯作者：
KUPFER, DJ
影响因子：
2.8
作者：
N. Avis;S. Crawford;R. Stellato;Christopher Longcope
通讯作者：
N. Avis;S. Crawford;R. Stellato;Christopher Longcope